Psychiatric and central nervous system (CNS) conditions constitute a huge area of unmet need with respect to drug therapy. Depression, dementia, and psychosis, in particular, are disorders that affect significant proportions of the population in the major pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). Current treatments for these disorders leave much to be desired with regard to potency, suitability, reliability, and side effects; thus, efforts to develop new drugs in the CNS/psychiatric arena are even more intense than in other therapeutic fields. The single greatest indicator of this R&D focus is the ever-increasing stream of patent applications in the psychiatric field.

(Photo: )

Intellectual property (IP), or more specifically patenting, represents unique scientific, commercial, and legal perspectives for evaluating the potential of a pharmaceutical company and its R&D assets. Trends in CNS/Psychiatric Drug Patenting: A Competitive and Pharmacological Assessment of Current and Projected R&D is a new report published by Decision Resources, Inc. This report demonstrates how patent activity information relating to psychiatric drug development can reveal patterns and trends with regard to disease indications, company strategies, and pharmacological mechanisms.

The analyses offered in this report are drawn from a custom database designed to facilitate competitive assessments and to spotlight licensing candidates in a critical area of CNS drug development. Early sections of the report summarize the strategic uses of pharmaceutical IP information, the nature of the patenting process, and the features and construction of the database. The balance of the report delivers quantitative and qualitative analyses and correlations. Key features of this report include the following:

  * Analysis of trends in psychiatric drug patent activity over time by   disorder, pharmacological mechanism, and company.   * Analyses of 11 psychiatric drug IP estates.   * Three case studies of strategic uses of psychiatric drug patenting.   * Profiles of companies that excel in specific areas of research or that   are best positioned to meet future development and launch targets-among   them Pfizer, AstraZeneca, Novartis, Lundbeck, Neurogen, Janssen, Glaxo   Wellcome, Neurosearch, Aventis, and Neurocrine Biosciences.  

Trends in CNS/Psychiatric Drug Patenting is available for $3,500.00. Contact: Cindy Ohlman, 781.296.2521 (telephone), 781.296.2525 (fax), or (e-mail). In Europe, contact Francoise Bidart, +32.2.351.4082 (telephone), +32.2.351.2347 (fax), or (e-mail). In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (telephone), +81.3.5401.2617 (fax), or (e-mail).

Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends.


AP Archive:

PRN Photo Desk, 888-776-6555 or 201-369-3467

SOURCE: Decision Resources, Inc.

Contact: Cindy Ohlman of Decision Resources, 781-296-2521, or

Decision Resources Study Analyzes Emerging Therapies and Investigational Approaches to the Treatment of Schizophrenia

View Now